Non-organic Solvent Method of Extracting N-Acetyl glucosamine from a fermentation broth

从发酵液中提取N-乙酰氨基葡萄糖的非有机溶剂法

• 批准号: 555617-2020
• 负责人: Leaver, Chad
• 金额: $ 1.03万
• 依托单位: Seneca College of Applied Arts and Technology
• 依托单位国家: 加拿大
• 项目类别: Applied Research and Development Grants - Level 1
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=705861
• 关键词: Non; organic; Solvent; Method; Extracting

Wellesley Therapeutics Inc., is a Toronto-based pharmaceutical company, currently marketing two GlcNAc (GlcNAc) containing products under the trade name Ultimate Glucosamine® and Villicote®. Wellesley's current purification process for GlcNAc requires the use of a multistep, organic solvent based, extraction and precipitation methodology. This method is costly, has negative effects on the environment and has safety concerns - expensive explosion proof processing is required. Wellesley is looking to collaborate with Seneca's School of Biological Sciences and Applied Chemistry (BSAC) to adopt a green chemistry approach to product recovery and purification. This approach will incorporate the physical solubility properties of GlcNAc to eliminate the need for organic solvent associated precipitation. Wellesley is engaged in the clinical development of GlcNAc for multiple sclerosis, muscular dystrophy and Parkinson's disease. Claims for the treatment of these indications will require Wellesley to file a new drug application. This application requires a detailed description of physical and chemical manufacturing processes and controls for production. The experimental work carried out at Seneca will translate to a detailed description and rationale for the intended commercial production methods

Wellesley Therapeutics Inc.是一家总部位于多伦多的制药公司，目前销售两个GlcNAC（GLCNAC），其中包含商品名称UltimateGlucosamine®和Villicote®的产品。韦尔斯利当前的GLCNAC纯化过程需要使用基于有机溶液的多步，提取和降水方法。此方法成本高昂，对环境有负面影响，并且存在安全问题 - 需要昂贵的爆炸性处理。韦尔斯利（Wellesley）希望与塞内卡（Seneca）的生物科学学院和应用化学学院（BSAC）合作，以采用绿色化学方法来进行产品恢复和净化。这种方法将结合GlcNAC的物理溶解度，以消除有机溶液相关的降水的需求。 韦尔斯利（Wellesley）从事多发性硬化症，肌肉营养不良和帕金森氏病的GlcNAC临床发展。治疗这些迹象的索赔将要求韦尔斯利提交新的药物申请。该应用需要详细描述物理和化学制造过程和生产的控制。在塞内卡（Seneca）进行的实验工作将转化为预期商业生产方法的详细说明和理由